Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Pacing at 5.9% CAGR Boosted by FDA Approval for Prolastin C, Forecast Till 2026
The Global Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market has been boosted by recent FDA approval for Prolastin-C. According to a report published by Fortune Business Insights, titled "AATD Augmentation Therapy: Global Analysis, Insights, and Forecast, 2019-2026", the market will be valued at US$ 1959.8 Mn by the end of 2025. The estimated rise in market value from its 2017 value of US$ 1115.5 Mn implies that the market will exhibit a CAGR of 5.9% in the forecast period. Fortune...
View full press release